Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

OASIS — oral semaglutide in obesity

The weight-management programme for high-dose oral semaglutide.

The weight-management programme for high-dose oral semaglutide.

Sponsor class: Manufacturer-sponsored. First record: 2021.

Showing 0 records on this page

Records in this programme

4 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
OASIS-1Semaglutide, oralPhase 3ReportedRandomised, double-blind, placebo-controlled6672023Moderate
OASIS-1-ADHERENCEprogramme recordSemaglutide, oralPhase 3ReportedObservational—2023Very low
OASIS-1-BIOMARKERprogramme recordSemaglutide, oralPhase 3ReportedRandomised, double-blind, placebo-controlled—2023Very low
OASIS-1-OLEprogramme recordSemaglutide, oralPhase 3ReportedSingle-arm open-label—2023Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.